(SOURCE: MASSACHUSETTS GENERAL HOSPITAL) – The combined results of two ovarian cancer screening trials suggest that a personalized strategy involving frequent screening of high-risk women could improve the chance that tumors are detected at early stages when they are easier to treat. As reported in a paper published in Clinical Cancer Research, these trials imply that a […]
(SOURCE: ROCKEFELLER UNIVERSITY PRESS) – Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the study “Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair […]
(SOURCE: CANCER RESEARCH UK) – Scientists might be able to quickly predict how ovarian cancer patients are likely to respond to chemotherapy treatment using a simple blood test, according to a Cancer Research UK-funded study published in PLOS Medicine. In a study of 40 patients with high grade serous ovarian cancer, the researchers monitored tumour DNA […]
(SOURCE: MAYO CLINIC) Researchers at Mayo Clinic have identified an enzyme called UCHL3 that regulates the BRCA2 pathway, which is important for DNA repair. Results of this research are published online in Genes & Development. “DNA encodes the blueprints for our body, and DNA repair is a fundamental mechanism to prevent the accumulation of mutations in […]
(SOURCE: STANFORD MEDICINE) Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice. A baseball glove is typically made from leather. If a new design made gloves more attractive to baseballs — catching them at higher rates than the typical glove — would it be a […]
(Yale) According to a recent article published in Yale News, in a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
(THE WISTAR INSTITUTE) According to a recent press release, treating ovarian cancer with platinum-based chemotherapy drugs such as cisplatin is initially very effective, with about four out of five patients responding favorably. However, most of these patients quickly become resistant to chemotherapy and may not respond as well to this standard treatment for the disease.
(BOSTON UNIVERSITY MEDICAL CENTER) According to an article recently published by Boston University Medical Center, a new study has identified an effective combination therapy for treating ovarian cancer cells.
(Myeloma Research News) According to a recent article published Myeloma Research News, patients with high-risk multiple myeloma may benefit from an experimental immunotherapy from SELLAS Life Sciences called galinpepimut-S, following an autologous stem cell transplant (ASCT). The data was gathered from a Phase 2 clinical trial which shows that the agent nearly doubles the progression-free survival rates […]
(PR Newswire) Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its SureSeq myPanel™ NGS Custom Cancer Panels to provide scientists with completely customized, pre-optimized next generation sequencing (NGS) probe panels relevant to their research. The comprehensive library of gene content covers key cancer types including, myeloid, chronic lymphocytic leukemia (CLL), ovarian and breast. Utilizing hybridisation-based capture, […]
(NY Times) According to a recently published article in the NY Times, from 2002 to 2012 the death rate from ovarian cancer declined in the United States by 16 percent. This percentage places the U.S. somewhere in the middle among a list of 47 countries whose ovarian cancer rates were published in Annals of Oncology study.